Watch the entire 2021 Mid-Year Update here:    • 2021 Moyad + Scholz Mid-Year Update |...  

Intermittent hormone therapy is a treatment protocol that intends to improve the quality of life in men with incurable prostate cancer that is responding well to treatment without sacrificing longevity. Although large clinical trials have demonstrated no significant difference in cancer progression or survival between continuous and intermittent hormone therapy, the practice is still somewhat controversial depending on the physician. Here, public health expert Mark Moyad, MD, MPH asks medical oncologist Celestia Higano, MD about her experience treating patients with intermittent hormone therapy.

Don’t know your stage? Take the quiz: Visit http://www.prostatecancerstaging.org

To learn more about prostate cancer visit http://www.pcri.org

Who we are:

The Prostate Cancer Research Institute (PCRI) is a 501(c)(3) not-for-profit organization that is dedicated to helping you research your treatment options. We understand that you have many questions, and we can help you find the answers that are specific to your case. All of our resources are designed by a multidisciplinary team of advocates and expert physicians, for patients. We believe that by educating yourself about the disease, you will have more productive interactions with your medical professionals and receive better-individualized care. Feel free to explore our website or call our free helpline at 1 (800) 641-7274 with any questions that you have. Our Federal Tax ID # is 95-4617875 and qualifies for maximum charitable gift deductions by individual donors.

The information on the Prostate Cancer Research Institute's YouTube channel is provided with the understanding that the Institute is not engaged in rendering medical advice or recommendation. The information provided in these videos should not replace consultations with qualified health care professionals to meet your individual medical needs.

#CelestiaHiganoMD #MarkMoyadMD #ProstateCancer